KOSDAQBiotech & Pharma358570

GI Innovation

₩6,990▼ 0.14%2026-11-18 close
Market Cap
₩451B
Turnover
₩1.3B
Volume
180K
Shares out.
64.5M
PER
—
PBR
5.0×
EPS
-₩679
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

GI Innovation: Awaiting Proof of Deal Revenue

GI Innovation's earnings structure depends on whether clinical data convert into licensing deals and milestones, and it has posted operating losses for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

  1. 1

    Annual revenue reached KRW 5.84 billion in 2025, the largest of 2022–2025, but fell to KRW 24.28 million in 2024, showing wide swings tied to the timing of milestone inflows.

  2. 2

    The operating loss narrowed from KRW 68 billion in 2022 to KRW 40.7 billion in 2025, but quarterly losses widened again to KRW 12.4 billion, KRW 14.4 billion and KRW 15.7 billion in the first three quarters of 2026.

  3. 3

    In April 2026 GI-102 received FDA clearance for a Phase 1b/2 trial combined with Janssen's pasritamig, a J&J subsidiary's drug, and the company said Korean regulators also approved a melanoma Phase 2 trial comparing it directly with Keytruda monotherapy.

  4. 4

    At the end of 2025 total equity was KRW 116.5 billion and total liabilities KRW 11 billion, while operating cash flow was -KRW 32.3 billion in 2025, so the pace of cash burn is the next item to watch.

  5. 5

    Money Today reported that no follow-on deals have followed the large Greater China licensing of GI-101A, making it a key question whether clinical data will lead to actual contracts.

02

Business structure

GI Innovation is a biotech company that runs drug discovery end to end on its proprietary bispecific fusion protein platform, GI-SMART, from target selection and lead optimization to production cell line construction.

Its core pipeline consists of the immuno-oncology candidates GI-101A and GI-102 and the allergy therapy GI-301 (YH35324), and the company said all three have entered Phase 2.

GI-101A is a fusion protein combining CTLA-4 inhibition with an IL-2-based immune activation mechanism, while GI-102 is built on a CD80 and IL-2v3 fusion designed to address the limits of earlier IL-2 therapies, which can expand regulatory T cells.

GI-301 has been licensed to Maruho in Japan and to Yuhan in Korea, and a report said the 2023 Maruho deal generated KRW 5.3 billion in revenue.

In April 2026 GI-102 received clearance for a trial combined with pasritamig from Janssen, a J&J subsidiary, and Korean approval for a melanoma Phase 2 trial comparing it directly with Keytruda.

Following a Merck (MSD) Keytruda combination trial, J&J also joined a GI-102 combination trial, adding to the company's big pharma collaborations.

Revenue comes from licensing contracts such as upfront payments and development milestones, and one report noted that revenue recognizable as upfront-type income has been limited because no additional licensing deals followed the listing.

GI-128, derived from the platform, is a dual-antibody macrophage engager targeting PD-L1 and LILRBs at the same time and remains at the preclinical stage. The next-generation pulmonary arterial hypertension candidate GI-214 has reportedly reached the patent filing stage.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩0-₩10.7B—
2025Q4₩5.5B-₩7.2B−130.7%
2026Q1₩0-₩12.4B—
2026Q2₩0-₩14.4B—
2026Q3₩0-₩15.7B—
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩3.5B-₩68B-₩79.8B−1941.5%−83.5%11.2%
2023₩5.3B-₩53.3B-₩55.5B−1002.2%−77.4%13.4%
2024₩24,281,460-₩48.3B-₩58.8B−198751.9%−202.4%57.6%
2025₩5.8B-₩40.7B-₩35.1B−696.4%−30.2%9.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On the DART-filed annual figures, revenue was KRW 3.5 billion in 2022, KRW 5.32 billion in 2023 (up 52.0% year on year), KRW 24.28 million in 2024 (down 99.5%), and KRW 5.84 billion in 2025 (up 23,943.4%). Within 2022–2025, 2025 was the largest year and 2024 the smallest.

The sharp swings reflect the timing of upfront payments and milestones recognized under licensing contracts. The 2023 revenue came from the GI-301 licensing to Maruho in Japan, while the 2025 revenue reflects a GI-301 milestone from the Yuhan deal, according to press reports.

The near-zero revenue in 2024 coincided with a period when no additional licensing deals produced recognizable revenue. The operating loss shrank from KRW 68 billion in 2022 to KRW 53.3 billion in 2023, KRW 48.3 billion in 2024 and KRW 40.7 billion in 2025, with losses recorded in each of the four years.

The operating margin reached -198,751.9% in 2024 because the revenue base was so small, which shows how thin the revenue base is. Net loss attributable to controlling shareholders was KRW 79.8 billion in 2022, KRW 55.5 billion in 2023, KRW 58.8 billion in 2024 (losses widened) and KRW 35.1 billion in 2025.

At the end of 2025 the debt ratio was 9.4%, total equity was KRW 116.5 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 11 billion.

Quarterly operating losses narrowed from KRW 10.7 billion in the third quarter of 2025 to KRW 7.19 billion in the fourth quarter, then widened to KRW 12.4 billion, KRW 14.4 billion and KRW 15.7 billion in the first three quarters of 2026.

The net loss attributable to controlling shareholders of KRW 14.9 billion in the third quarter of 2026 widened from a year earlier, and the four-quarter total from the fourth quarter of 2025 through the third quarter of 2026 was KRW 44.6 billion.

05

Industry analysis

In immuno-oncology, combination strategies are becoming more important than single agents, and the company's CEO said it intends to secure data alongside global partners within this trend.

GI-102 is designed to be combined with a T-cell engager from J&J, and a Hanyang Securities analyst said in an April 2026 report that GI-102 is an IL-2 protein designed to be safer than GI-101 and has strengths in combination dosing.

The same report noted that many large global pharma deals began as clinical collaborations, arguing this partnership could raise expectations for commercialization.

On the other hand, IL-2-based therapies have been criticized for expanding regulatory T cells along with activating immune cells, which limits anticancer effect, so how the candidates address that limit will shape their competitive position.

GI Innovation has signed large licensing deals but has not followed them with additional contracts, which is cited as a relative weakness. Money Today pointed out that no follow-on results have come after the Greater China licensing of GI-101A worth KRW 900 billion.

GI-301 has been licensed to Yuhan and Maruho, so further licensing of that asset is closely watched. Analysts also note that negative data from a combination trial could weigh on partners, so the results of combination programs will shape the company's standing in the sector.

06

Outlook

In early 2026 a company official said major pipeline data would begin to materialize this year and that additional milestones were expected. GI-101A's Phase 1 data were selected for an oral presentation at ASCO 2026, which reports said was scheduled for late May 2026.

An April 2026 report said the first patient dosing in the GI-101A Phase 2 trial was scheduled for that month, and the trial is planned to run for about three years in Korea and the United States in patients with metastatic castration-resistant prostate cancer.

GI-102 has a planned Phase 1b/2 trial in the United States, named JET-201, covering up to 107 patients over about three years. In April 2026 the company said its GI-102 monotherapy subcutaneous, ADC combination and Keytruda combination trials were each progressing. GI-108 is in Phase 1.

On listing requirements, the 2025 ratio of the loss on capital attributable to listing rules relative to equity was 29.65%, down sharply from 203.11% a year earlier, though a February 2026 report said the grace period for the listing maintenance requirement would end in about a year.

The next periodic report is the 2026 annual report, which will show whether licensing milestones were recognized as revenue. Whether quarterly operating losses, which widened through the first three quarters of 2026, continue to expand is also a point to watch.

07

Valuation

PER
—
PBR
5.0×
ROE
-44.8%
EPS
-₩679
BPS
₩1,412
Dividend per share
₩0

Because net losses attributable to controlling shareholders have continued over the last four quarters, the PER cannot be calculated, so multiple comparisons should center on the relationship between book value and market capitalization.

The price-to-book ratio was in a high range at each year-end from 2023 through 2025 and is currently in a range with a large premium over net asset value.

With all of total equity attributable to controlling shareholders, a market capitalization well above net assets can be read as the market pricing in expectations for the pipeline rather than current earnings.

Because operating losses were recorded in every year from 2022 through 2025 on the DART-filed figures, earnings-based multiple comparisons are difficult. The company pays no dividend, so there is no dividend basis for comparison.

Pipeline value depends heavily on clinical data and contract outcomes, so the same multiple can be interpreted differently depending on deal results. Since losses have continued since the third quarter of 2025, the pace of capital consumption and any further capital raising should be considered alongside the multiple.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Higher visibility of clinical data

GI-101A earned an ASCO 2026 oral presentation slot on Phase 1 data alone, which is cited as a sign of higher pipeline visibility. GI-102 obtained regulatory clearances in both the United States and Korea in April 2026, increasing its monotherapy and combination trials at the same time. Data confirmed in patients could serve as the basis for licensing negotiations, which is the main bull point.

Combination trials with big pharma

GI-102 signed a clinical trial collaboration and supply agreement with Janssen for pasritamig in March 2026, and J&J joined after Merck's Keytruda collaboration. A Hanyang Securities analyst described GI-102 in an April 2026 report as an IL-2 protein with strengths in combination dosing.

The same report pointed out that many large global pharma deals started as clinical collaborations, which could raise commercialization expectations.

Room for revenue structure to shift

Revenue of KRW 5.84 billion in 2025 was reported to reflect a GI-301 milestone, and the company expects additional milestones to flow in depending on this year's pipeline data.

The 2025 loss-on-capital ratio under the listing rules was 29.65%, down sharply from 203.11% a year earlier, easing concerns about listing requirements. Because the revenue base is thin, a single milestone could change the earnings structure, which is the key bull point.

09

Bear factors

Widening losses

Operating losses widened every quarter in 2026, to KRW 12.4 billion in the first quarter, KRW 14.4 billion in the second and KRW 15.7 billion in the third.

The wider operating losses carried through to the net loss attributable to controlling shareholders, which was larger than a year earlier, and whether it narrows next quarter is the point to check. Losses have continued for five consecutive quarters since the third quarter of 2025, with no sustained narrowing yet.

No follow-on licensing deals

Revenue in 2024 was KRW 24.28 million, down 99.5% from the prior year, and there is a view that no clear additional licensing deals have followed the listing. Money Today reported that no follow-on results have come after the KRW 900 billion Greater China licensing deal. A January 2026 report noted that results remain far from the earnings targets presented at the listing.

Cash burn and reliance on capital raising

Operating cash flow improved from -KRW 62.6 billion in 2022 to -KRW 32.3 billion in 2025 but remains negative. A January 2026 report noted that cash was secured through a rights offering amid weak revenue and continued losses.

With total equity of KRW 116.5 billion at the end of 2025, all attributable to controlling shareholders, whether further capital is raised will shape financial flexibility.

10

Risk factors

Clinical outcome risk

GI-101A, GI-102 and GI-301 are all at the Phase 2 stage, so disappointing results could weaken both licensing talks and pipeline value. Analysts note that negative data from a combination trial could weigh on partners and dilute the competitiveness of standalone therapy. The combination strategy for GI-102 also depends on results from the J&J and Merck programs.

Listing maintenance and financial risk

The 2025 loss-on-capital ratio eased to 29.65%, but a February 2026 report said the grace period for listing maintenance requirements is about a year away. Operating losses have continued for five consecutive quarters since the third quarter of 2025, and operating cash flow remains negative. Repeated capital raising would also bring dilution to shareholder value.

Partner dependence and deal timing risk

Revenue depends on licensing contracts and milestones, so delays in deals push back revenue recognition. Key collaborations for GI-101A and GI-102 rely on global partners such as J&J, Merck and Janssen, and changes in partner strategy could affect the timetable. With further GI-301 licensing uncertain, the timing of milestone inflows is hard to predict.

11

What to watch next

  1. December 2026 onward (ad hoc disclosures)

    Whether first-patient dosing and progress updates are disclosed for the GI-102 melanoma Phase 2 and the JET-201 trial. Confirmed progress would indicate how quickly the combination strategy is advancing.

  2. March 31, 2027

    Filing deadline for the 2026 annual report. It will show 2026 full-year revenue and operating loss and whether licensing milestones were recognized as revenue.

  3. May 15, 2027

    Filing deadline for the Q1 2027 quarterly report. The key check is whether the operating loss narrows from the KRW 15.7 billion level of the third quarter of 2026 and whether additional milestones come in.

  4. Around early 2027

    Timing of the end of the grace period for listing maintenance requirements. A February 2026 report put it about a year away, and whether the requirements, including the loss-on-capital ratio, are met is the check point.

12

Overall view

GI Innovation posted operating losses every year from 2022 through 2025, and its 2025 revenue of KRW 5.84 billion reflected a GI-301 milestone.

Annual operating loss narrowed from KRW 68 billion in 2022 to KRW 40.7 billion in 2025, but quarterly operating losses widened to KRW 12.4 billion, KRW 14.4 billion and KRW 15.7 billion across the first three quarters of 2026.

On the positive side are the ASCO 2026 oral presentation selection for GI-101A, FDA and Korean clearances for GI-102, and combination trial structures with J&J and Merck.

On the negative side are the lack of clear follow-on licensing deals after the listing, operating cash flow of -KRW 32.3 billion in 2025, and reliance on capital raising. Total equity of KRW 116.5 billion and total liabilities of KRW 11 billion at the end of 2025 provide the financial baseline.

The next checkpoints are how licensing milestones are recognized in the 2026 annual report and the trend in operating loss in the first quarter of 2027. This report does not present an investment opinion, rating or target price and is provided for information only.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. v.daum.net
  2. investing.com
  3. m.thebell.co.kr
  4. needinfo.co.kr
  5. comp.fnguide.com
  6. vegannews.co.kr
  7. newstown.co.kr
  8. m.news.nate.com
  9. jobkorea.co.kr
  10. newsway.co.kr
  11. gi-innovation.com
  12. v.daum.net
  13. biz.heraldcorp.com
  14. newsway.co.kr
  15. hitnews.co.kr
  16. gi-innovation.com
  17. mt.co.kr
  18. mt.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis